评估伤口愈合的安全性和有效性研究
一项随机、双盲、载体对照、剂量递增研究,以评估皮内给药 AIV001 在切口伤口愈合中的安全性、药代动力学和药效学
To evaluate the safety, efficacy and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with incisional wounds
研究概览
详细说明
This is primarily a safety study to evaluate the safety of AIV001 when administered near incisional wounds. A unique model was used to assess incisional scarring, safety and biomarker assessments. Women electing to have the abdominoplasty procedure were enrolled in the study and abdominal incisions were generated on the abdominal skin. Up to 10 incisions were made on abdominal skn and treated as assigned. And data collection was conducted up to day 49 when the subjects were exited from the study and the abdominoplasty procedure performed. Exploratory efficacy measures were collected and pharmacokinetic profiles determined.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Folsom、California、美国、95630
- Kaufman and Davis Plastic Surgery
-
San Diego、California、美国、92121
- Cosmetic Laser Dermatology
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Eligible for an abdominoplasty
- Nonsmoker
- Fitzpatrick I-IV
- Weight >45Kg
- BMI <= 35
Exclusion Criteria:
- Existing scars in study area, active infection
- Any medical history or present conditions that may increase the risk associated with study participation or investigational product administration and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:0.033% versus Vehicle
One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle. |
Intradermal injection
其他名称:
|
|
实验性的:0.1% versus Vehicle
One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle. |
Intradermal injection
其他名称:
|
|
实验性的:0.3% versus Vehicle
One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle. |
Intradermal injection
其他名称:
|
|
实验性的:1% versus Vehicle
One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle. |
Intradermal injection
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse events
大体时间:Day 1 through Day 49
|
Local and systemic adverse events |
Day 1 through Day 49
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Efficacy using Patient and Observer Scar Assessment Scale (6 parameters, 1 normal to 10 worst imaginable)
大体时间:Day 7 through 49
|
Evaluation of the healing of the wounds |
Day 7 through 49
|
|
Modified Vancouver Scar Scale (4 parameters, 0 = normal to 3 or 4 = severe)
大体时间:Day 7 through 49
|
Evaluation of the healing wounds |
Day 7 through 49
|
|
100 mm Visual Analogue Scale (0 = normal to 10 = poor scar)
大体时间:Day 7 through 49
|
Evaluation of healing wounds |
Day 7 through 49
|
合作者和调查者
调查人员
- 研究主任:James Milbauer, MD、Novella Clinical
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.